Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative...
7 insider purchases on record · latest filing 2026-07-10.
Insiders have also filed 9 sale transactions at EVMN.